Zobrazeno 1 - 10
of 407
pro vyhledávání: '"PAUL NATHAN"'
Autor:
Alexander C.J. van Akkooi, Mario Mandala, Paul Nathan, Andrew Haydon, Michael Postow, Piotr Rutkowski
Publikováno v:
EJC Skin Cancer, Vol 2, Iss , Pp 100021- (2024)
Adjuvant (ADJ) systemic therapy has transformed melanoma treatment during the past decade. There are, however, still important unanswered questions that lead to debates on the utility and place of ADJ therapy for melanoma. When ADJ trials are reporte
Externí odkaz:
https://doaj.org/article/420bba202ec2421aaaf7ece1ccde632b
Autor:
Angela Meade, Elena Frangou, Babak Choodari-Oskooei, James Larkin, Tom Powles, Grant D. Stewart, Laurence Albiges, Axel Bex, Toni K. Choueiri, Ian D. Davis, Tim Eisen, Alison Fielding, Craig Gedye, David J. Harrison, Rick Kaplan, Salena Mulhere, Paul Nathan, Grisma Patel, Jay Patel, Hannah Plant, Alastair Ritchie, Hannah Rush, Clare Shakeshaft, Martin R. Stockler, Cristina Suarez, Jemima Thompson, Nat Thorogood, Balaji Venugopal, Mahesh K.B. Parmar
Publikováno v:
Contemporary Clinical Trials Communications, Vol 42, Iss , Pp 101381- (2024)
Clinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external factors can impact recruitment and reporting plans. An example is a new standard of care becoming
Externí odkaz:
https://doaj.org/article/152a532dd63f4c618fd32817ead311e1
Autor:
Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown
Publikováno v:
Health Technology Assessment, Vol 28, Iss 45 (2024)
Background There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment
Externí odkaz:
https://doaj.org/article/f262d31cdee84d25b7afd7439e0362e7
Autor:
Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3
Externí odkaz:
https://doaj.org/article/e21e585079dc450abadbe8a2b44d6e73
Autor:
Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM wit
Externí odkaz:
https://doaj.org/article/b89b2a51187f4158bed6c6e774c8ce00
Autor:
Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Irena Trbojević-Akmačić, Andrew M. Thomas, Laura A. Bolte, Johannes R. Björk, Jahlisa S. Hooiveld-Noeken, Ruth Board, Mark Harland, Julia Newton-Bishop, Mark Harries, Joseph J. Sacco, Paul Lorigan, Heather M. Shaw, Elisabeth G.E. de Vries, Rudolf S.N. Fehrmann, Rinse K. Weersma, Tim D. Spector, Paul Nathan, Geke A. P. Hospers, Peter Sasieni, Veronique Bataille, Gordan Lauc, Mario Falchi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are mo
Externí odkaz:
https://doaj.org/article/50b511b7f9af46e6993f096da9d33865
Autor:
Adree Khondker, Michael Groff, Sophia Nunes, Carolyn Sun, Natasha Jawa, Jasmine Lee, Vedran Cockovski, Yasmine Hejri-Rad, Rahul Chanchlani, Adam Fleming, Amit Garg, Nivethika Jeyakumar, Abhijat Kitchlu, Asaf Lebel, Eric McArthur, Luc Mertens, Paul Nathan, Rulan Parekh, Serina Patel, Jason Pole, Raveena Ramphal, Tal Schechter, Mariana Silva, Samuel Silver, Lillian Sung, Ron Wald, Paul Gibson, Rachel Pearl, Laura Wheaton, Peter Wong, Kirby Kim, Michael Zappitelli
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 9 (2022)
Background: Approximately 30% of childhood cancer survivors (CCSs) will develop chronic kidney disease (CKD) or hypertension 15 to 20 years after treatment ends. The incidence of CKD and hypertension in the 5-year window after cancer therapy is unkno
Externí odkaz:
https://doaj.org/article/d0058a0c6d6046d79a393a2d94f55af9
Publikováno v:
JMIR Human Factors, Vol 9, Iss 3, p e37606 (2022)
BackgroundSurvivors of childhood cancer are at lifelong risk of morbidity (such as new cancers or heart failure) and premature mortality due to their cancer treatment. These are termed late effects. Therefore, they require lifelong, risk-tailored sur
Externí odkaz:
https://doaj.org/article/6a7bec47c5f646eab4803a25d944fca3
Autor:
Niccolò Rossi, Karla A. Lee, Maria V. Bermudez, Alessia Visconti, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Julia Newton-Bishop, Mark Harland, Heather M. Shaw, Mark Harries, Joseph Sacco, Ruth Board, Paul Lorigan, Elisabeth G.E. de Vries, Nicola Segata, Leonie Taams, Sophie Papa, Tim D. Spector, Paul Nathan, Rinse K. Weersma, Geke A.P. Hospers, Rudolf S.N. Fehrmann, Veronique Bataille, Mario Falchi
Publikováno v:
EBioMedicine, Vol 83, Iss , Pp 104235- (2022)
Summary: Background: Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/2653e1f206bf4483825a0683e7b29ab7
Autor:
Paolo A. Ascierto, Lisa H. Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A. Emens, Silvia Formenti, Filip Janku, Samir N. Khleif, Tomas Kirchhoff, Alessandro Morabito, Yana Najjar, Paul Nathan, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Bradley I. Reinfeld, Heath D. Skinner, John Timmerman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-20 (2021)
Abstract Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with mel
Externí odkaz:
https://doaj.org/article/9bf022f4904a44f583c759901d1d9f53